European Archives - Page 1087 of 1094 - European Medical Journal

EMJ Oncology 2013

I am very excited to introduce to you our inaugural edition of European Medical Journal – Oncology.

The Future of Chronic Lymphocytic Leukaemia Treatment: Balancing Efficacy, Safety and Cost

A Review of the Mundipharma International Ltd Organised Symposium, at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Cologne…

Extreme Hypofractionated Image-Guided Radiotherapy for Prostate Cancer

An emerging body of data suggests that hypofractionated radiation schedules, where a higher dose per fraction is delivered in a smaller number of…

Prostate Cancer and Inflammation: The Role of miRNAs

Approximately 15-20% of all human cancers are assumed to be a result of infection and chronic inflammation due to a constant supply of cytokines and…

Role of Positron Emission Tomography with Fluorodeoxyglucose in Prostate Cancer

Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) has undergone explosive growth in clinical applications and has emerged…

Genomic Testing in International Guidelines

Human breast cancer was solely classified based on clinical and immunohistochemical (IHC) findings in the past. A growing body of evidence suggests that…

Metastasis of Ductal Breast Carcinoma to the Vagina: A Case Report

Primary cancers of the vagina are rare, and so vaginal tumours are likely to represent metastasis from another site. Although breast cancer is a common…

New Cervical Cancer Screening Guidelines on Both Sides of the Atlantic

Large population-based trials showed that the human papillomavirus (HPV) DNA test can be even more effective than Pap tests in preventing cervical cancer.

Intensity-Modulated Radiotherapy in the Treatment of Pancreatic Adenocarcinoma: A Review

Pancreatic cancer remains one of the leading causes of cancer deaths. Despite improvements in imaging, surgical techniques, chemotherapy agents, and…

Key Advances in the Systemic Therapy for Soft Tissue Sarcomas: Current Status and Future Directions

Soft tissue sarcomas (STS) represent a heterogeneous group of diverse neoplasms of mesenchymal origin. Once relapsed from standard therapy, STS patients…